Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXACT SCIENCES CORPEXAS · Entity 56619 | Director | October 31, 2023 | November 01, 2023 |
| INSULET CORPPODD · Entity 3516 | Director | May 20, 2026 | May 21, 2026 |
| Molekule Group, Inc.AERC · Entity 113413 | Director | June 01, 2022 | June 09, 2022 |
| NovoCure LtdNVCR · Entity 4494 | Director | June 03, 2026 | June 05, 2026 |
| Renalytix plcRNLX · Entity 7446 | Director | July 01, 2023 | July 03, 2023 |
| STRYKER CORPSYK · Entity 369 | President and COO | August 01, 2021 | August 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXACT SCIENCES CORP
Report date October 31, 2023 · Filed November 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,694 |
Reported balance
After 2023-10-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-10-31 · Grant · Acquired 5,694 · Balance 5,694 F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy and vest in three equal annual installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy and vest in three equal annual installments beginning on the first anniversary of the grant date.
INSULET CORP
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,024 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 1,660 · Balance 33,024 F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027.
Molekule Group, Inc.
Report date June 01, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 55,289 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 55,289 · Balance 55,289 F1: Each restricted stock unit represents a contingent right to receive one share of AERC common stock. F2: The restricted stock units vest in three equal annual installments beginning June 1, 2023. Any unvested restricted stock units will vest in full immediately prior to the consummation of a change in control (as defined in the award agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of AERC common stock.
F2: The restricted stock units vest in three equal annual installments beginning June 1, 2023. Any unvested restricted stock units will vest in full immediately prior to the consummation of a change in control (as defined in the award agreement).
NovoCure Ltd
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 25,898 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 25,898 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03 | Direct | 16,999 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Renalytix plc
Report date July 01, 2023 · Filed July 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 68,964 |
Reported balance
Holding disclosure · report date 2023-07-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 68,964 F1: The Ordinary Shares may be represented by American Depositary Shares, each representing two Ordinary Shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Expires 2032-04-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-07-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: The exercise price is 2.76 pounds sterling. The U.S. dollar equivalent of the exercise price is $3.48 using the Bank of England rate as of June 29, 2023 (1.00 pound sterling = $1.262). F2: One fourth (1/4th) of the shares subject to the option award vested on March 30, 2023, and one sixteenth (1/16th) of the shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each representing two Ordinary Shares.
F2: One fourth (1/4th) of the shares subject to the option award vested on March 30, 2023, and one sixteenth (1/16th) of the shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service.
F3: The exercise price is 2.76 pounds sterling. The U.S. dollar equivalent of the exercise price is $3.48 using the Bank of England rate as of June 29, 2023 (1.00 pound sterling = $1.262).
STRYKER CORP
Report date August 01, 2021 · Filed August 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 221,579 |
Reported balance
After 2021-08-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-08-01 · Exercise / conversion · Acquired 3,659 · Balance 221,579 F1: On August 1, 2021, 3,659 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock. F2: Includes 90 shares of Stryker Common Stock acquired pursuant to Stryker Corporation's Employee Stock Purchase Plan ("ESPP") as of June 30, 2021, the date of the latest available statement of the reporting person's ESPP holdings. |
| Common StockSEC Table I · non-derivative | Direct | 219,707 |
Reported balance
After 2021-08-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-08-01 · Tax withholding · Disposed 1,872 · Balance 219,707 |
| Restricted Stock Units granted 07/09/2018SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-01 · Exercise / conversion · Disposed 3,659 · Balance 0 F1: On August 1, 2021, 3,659 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy 401K | 5,504 |
Reported balance
Holding disclosure · report date 2021-08-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,504 |
Filing footnotes · ownership attribution and instrument terms
F1: On August 1, 2021, 3,659 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock.
F2: Includes 90 shares of Stryker Common Stock acquired pursuant to Stryker Corporation's Employee Stock Purchase Plan ("ESPP") as of June 30, 2021, the date of the latest available statement of the reporting person's ESPP holdings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MASIMO CORP
Report date June 10, 2026 · Filed June 12, 2026
Section 16 reporting ended · disclosed 2026-06-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Disposition to issuer · Disposed 2,608 · Balance 0 F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Disposition to issuer · Disposed 1,119 · Balance 0 F4: Represents the unvested portion of RSUs granted on April 23, 2026, which award of RSUs was to vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the date of grant. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") held by the Issuer's non-employee directors was canceled and converted into the right to receive an amount in cash equal to the Per Share Merger Consideration. F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration").
F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") held by the Issuer's non-employee directors was canceled and converted into the right to receive an amount in cash equal to the Per Share Merger Consideration.
F4: Represents the unvested portion of RSUs granted on April 23, 2026, which award of RSUs was to vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:39 UTC | MASIMO CORP MASI · Entity 39014 | Disposition to issuerRestricted Stock Units · Derivative | 1,119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-073535 · tm2617401-12_4seq1.xml · derivative · entry 2 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,119 shares Expires not disclosed F4 · derivative.exercise_price: Represents the unvested portion of RSUs granted on April 23, 2026, which award of RSUs was to vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the date of grant. F3 · price: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") held by the Issuer's non-employee directors was canceled and converted into the right to receive an amount in cash equal to the Per Share Merger Consideration. F1 · derivative.exercise_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") held by the Issuer's non-employee directors was canceled and converted into the right to receive an amount in cash equal to the Per Share Merger Consideration. F4 · derivative.exercise_date: Represents the unvested portion of RSUs granted on April 23, 2026, which award of RSUs was to vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the date of grant. F1 · derivative.expiration_date: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.expiration_date: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") held by the Issuer's non-employee directors was canceled and converted into the right to receive an amount in cash equal to the Per Share Merger Consideration. F4 · derivative.expiration_date: Represents the unvested portion of RSUs granted on April 23, 2026, which award of RSUs was to vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:39 UTC | MASIMO CORP MASI · Entity 39014 | Disposition to issuerCommon Stock | 2,608 | $180.00 | $469,440.00 |
DisclosureSEC source: 0001104659-26-073535 · tm2617401-12_4seq1.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2 · price: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration"). Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 16,999 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001451533-26-000002 · primarydocument.xml · derivative · entry 2 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,999 Underlying: Ordinary Shares · 16,999 shares Expires 2036-06-03 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001451533-26-000002 · primarydocument.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,898 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:53 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,945 | $15.77 | $46,444.71 |
DisclosureSEC source: 0001451533-26-000001 · primarydocument.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,288 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:37 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-26-000127 · form4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,024 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. Read SEC document |
| April 29, 2026 Filed May 5, 2026 21:03 UTC | MASIMO CORP MASI · Entity 39014 | Exercise / conversionRestricted Stock Units · Derivative | 1,225 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-26-000061 · wk-form4_1778014991.xml · derivative · entry 2 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,225 shares Expires 2035-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: These RSUs were granted on April 29, 2025 and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| April 29, 2026 Filed May 5, 2026 21:03 UTC | MASIMO CORP MASI · Entity 39014 | Exercise / conversionCommon Stock | 1,225 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-26-000061 · wk-form4_1778014991.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2026 Filed May 5, 2026 21:03 UTC | MASIMO CORP MASI · Entity 39014 | GrantRestricted Stock Units · Derivative | 1,119 | $178.71 | $199,976.49 |
DisclosureSEC source: 0000937556-26-000061 · wk-form4_1778014991.xml · derivative · entry 3 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,238 Underlying: Common Stock · 1,119 shares Expires 2036-04-23 F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F3 · derivative.exercise_date: These RSUs were granted on April 23, 2026 and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 16,697 | $0.00 Strike: $16.72 | $0.00 |
DisclosureSEC source: 0001562180-25-004557 · primarydocument.xml · derivative · entry 2 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,697 Underlying: Ordinary Shares · 16,697 shares Expires 2035-06-04 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004557 · primarydocument.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,233 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 999 | $17.32 | $17,299.18 |
DisclosureSEC source: 0001562180-25-004433 · primarydocument.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,018 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price. F3 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:11 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015658 · form4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,364 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2026. Read SEC document |
| April 29, 2025 Filed May 2, 2025 12:54 UTC | MASIMO CORP MASI · Entity 39014 | GrantRestricted Stock Units · Derivative | 1,225 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-25-000073 · wk-form4_1746190456.xml · derivative · entry 3 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,225 Underlying: Common Stock · 1,225 shares Expires 2035-04-29 F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F3 · derivative.exercise_date: These RSUs were granted on April 29, 2025 and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| April 29, 2025 Filed May 2, 2025 12:54 UTC | MASIMO CORP MASI · Entity 39014 | Exercise / conversionRestricted Stock Units · Derivative | 1,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-25-000073 · wk-form4_1746190456.xml · derivative · entry 2 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,383 shares Expires 2034-10-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: These RSUs were granted on October 16, 2024 and vested in full on the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| April 29, 2025 Filed May 2, 2025 12:54 UTC | MASIMO CORP MASI · Entity 39014 | Exercise / conversionCommon Stock | 1,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-25-000073 · wk-form4_1746190456.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 13:08 UTC | MASIMO CORP MASI · Entity 39014 | GrantRestricted Stock Units · Derivative | 1,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000937556-24-000100 · wk-form4_1729256883.xml · derivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,383 Underlying: Common Stock · 1,383 shares Expires 2034-10-16 F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU. F2 · derivative.exercise_date: These RSUs were granted on October 16, 2024 and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 20:13 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 5,000 | $225.84 | $1,129,200.00 |
DisclosureSEC source: 0001127602-24-023776 · form4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,586 F1 · price: The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $225.82 to $225.92. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:12 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 7,000 | $190.51 | $1,333,570.00 |
DisclosureSEC source: 0001127602-24-018360 · form4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,586 F1 · price: The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $189.11 to $192.11. Specifically: 1855 shares were sold in the range of $189.11 to $190.10, with a weighted average share price of $189.55; 3730 shares were sold in the range of $190.13 to $191.19, with a weighted average share price of $190.54; F2 · price: Footnote continued: 1415 shares were sold in the range of $191.20 to $192.11 with a weighted average share price of $191.68; The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 6,229 | $0.00 Strike: $23.13 | $0.00 |
DisclosureSEC source: 0001562180-24-004759 · primarydocument.xml · derivative · entry 3 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,229 Underlying: Ordinary Shares · 6,229 shares Expires 2034-06-04 F3 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 4,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004759 · primarydocument.xml · nonDerivative · entry 2 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,981 F2 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 964 | $23.89 | $23,027.45 |
DisclosureSEC source: 0001562180-24-004759 · primarydocument.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,964 F1 · price: This transaction was executed in multiple trades at prices ranging from $23.80 USD to $23.95 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:04 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,587 | $0.00 Strike: $40.60 | $0.00 |
DisclosureSEC source: 0001127602-24-016771 · form4.xml · derivative · entry 9 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,587 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:04 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,235 | $0.00 Strike: $28.87 | $0.00 |
DisclosureSEC source: 0001127602-24-016771 · form4.xml · derivative · entry 8 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,235 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:04 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,525 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001127602-24-016771 · form4.xml · derivative · entry 7 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,525 shares Expires 2025-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, which is fully vested, vested over a three-year period with 50% of the total award vesting on the first anniversary of the grant date and the remaining 50% of the award vesting equally on the second and third anniversaries of the grant date, which was May 13, 2015. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:04 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,920 | $0.00 Strike: $36.38 | $0.00 |
DisclosureSEC source: 0001127602-24-016771 · form4.xml · derivative · entry 6 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,920 shares Expires 2024-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, which is fully vested, vested over a three-year period with 50% of the total award vesting on the first anniversary of the grant date and the remaining 50% of the award vesting equally on the second and third anniversaries of the grant date, which was September 2, 2014. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:04 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 3,300 | $180.90 | $596,970.00 |
DisclosureSEC source: 0001127602-24-016771 · form4.xml · nonDerivative · entry 5 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,586 Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:04 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 3,587 | $40.60 | $145,632.20 |
DisclosureSEC source: 0001127602-24-016771 · form4.xml · nonDerivative · entry 4 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:04 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 5,235 | $28.87 | $151,134.45 |
DisclosureSEC source: 0001127602-24-016771 · form4.xml · nonDerivative · entry 3 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:04 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 5,525 | $27.37 | $151,219.25 |
DisclosureSEC source: 0001127602-24-016771 · form4.xml · nonDerivative · entry 2 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:04 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 3,920 | $36.38 | $142,609.60 |
DisclosureSEC source: 0001127602-24-016771 · form4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2024 Filed May 23, 2024 21:13 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016464 · form4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,619 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2025 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 16:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054026 · doc4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,694 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy and vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 6,277 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001562180-23-005016 · primarydocument.xml · derivative · entry 2 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,277 Underlying: Ordinary Shares · 6,277 shares Expires 2033-06-06 F2 · derivative.exercise_date: Options to buy 6,277 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:05 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 3,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005016 · primarydocument.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,928 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:16 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016719 · form4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,239 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 8,700 | $0.00 Strike: $77.25 | $0.00 |
DisclosureSEC source: 0001645113-22-000053 · wf-form4_165489184116868.xml · derivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Ordinary Shares · 8,700 shares Expires 2032-06-08 F1 · derivative.exercise_date: Options to buy 8,700 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2023 annual general meeting of shareholders. Read SEC document |
| June 01, 2022 Filed Jun 9, 2022 17:00 UTC | Molekule Group, Inc. AERC · Entity 113413 | GrantRestricted Stock Units · Derivative | 55,289 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069710 · tm2218078-2_4seq1.xml · derivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,289 Underlying: Common Stock · 55,289 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AERC common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning June 1, 2023. Any unvested restricted stock units will vest in full immediately prior to the consummation of a change in control (as defined in the award agreement). F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning June 1, 2023. Any unvested restricted stock units will vest in full immediately prior to the consummation of a change in control (as defined in the award agreement). Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:12 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015767 · form4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,396 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2023 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 11, 2022 Filed May 13, 2022 17:03 UTC | Molekule Group, Inc. AERC · Entity 113413 | GrantRestricted Stock Units · Derivative | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-060443 · tm2215465-2_4seq1.xml · derivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AERC common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning May 11, 2023. Any unvested restricted stock units will vest in full immediately prior to the consummation of a change in control (as defined in the award agreement). F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning May 11, 2023. Any unvested restricted stock units will vest in full immediately prior to the consummation of a change in control (as defined in the award agreement). Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 22:18 UTC | STRYKER CORP SYK · Entity 369 | Exercise / conversionRestricted Stock Units granted 07/09/2018 · Derivative | 3,659 | $0.00 | $0.00 |
DisclosureSEC source: 0000310764-21-000115 · wf-form4_162802909596663.xml · derivative · entry 4 Scannell Timothy J · CIK 0001451533 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On August 1, 2021, 3,659 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock. F1 · derivative.exercise_date: On August 1, 2021, 3,659 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock. F1 · derivative.expiration_date: On August 1, 2021, 3,659 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 22:18 UTC | STRYKER CORP SYK · Entity 369 | Tax withholdingCommon Stock | 1,872 | $270.94 | $507,199.68 |
DisclosureSEC source: 0000310764-21-000115 · wf-form4_162802909596663.xml · nonDerivative · entry 2 Scannell Timothy J · CIK 0001451533 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,707 Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 22:18 UTC | STRYKER CORP SYK · Entity 369 | Exercise / conversionCommon Stock | 3,659 | $0.00 | $0.00 |
DisclosureSEC source: 0000310764-21-000115 · wf-form4_162802909596663.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 1, 2021, 3,659 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock. F2 · balance_after: Includes 90 shares of Stryker Common Stock acquired pursuant to Stryker Corporation's Employee Stock Purchase Plan ("ESPP") as of June 30, 2021, the date of the latest available statement of the reporting person's ESPP holdings. Read SEC document |
| May 27, 2021 Filed May 28, 2021 20:12 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 808 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018313 · form4.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,387 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2022 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| March 21, 2021 Filed Mar 23, 2021 23:54 UTC | STRYKER CORP SYK · Entity 369 | Tax withholdingCommon Stock | 3,946 | $230.00 | $907,580.00 |
DisclosureSEC source: 0000310764-21-000044 · wf-form4_161654366914868.xml · nonDerivative · entry 2 Scannell Timothy J · CIK 0001451533 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,920 Read SEC document |
| March 21, 2021 Filed Mar 23, 2021 23:54 UTC | STRYKER CORP SYK · Entity 369 | GrantCommon Stock | 8,268 | $0.00 | $0.00 |
DisclosureSEC source: 0000310764-21-000044 · wf-form4_161654366914868.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,866 F1 · shares: Shares issued upon vesting of Performance Stock Units, and related dividend equivalents, that were earned based on the achievement of pre-established three-year average adjusted diluted net earnings per share goals and sales performance goals. F2 · balance_after: Includes 90 shares of Stryker Common Stock acquired pursuant to Stryker Corporation's Employee Stock Purchase Plan ("ESPP") as of December 31, 2020, the date of the latest available statement of the reporting person's ESPP holdings. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:48 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 7,929 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000028 · wf-form4_161489809030750.xml · derivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,929 Underlying: Ordinary Shares · 7,929 shares Expires 2031-03-01 F1 · derivative.exercise_date: These stock options will vest in equal parts on the first, second and third anniversary of the grant date. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:51 UTC | STRYKER CORP SYK · Entity 369 | GrantEmployee Stock Option granted 02/03/2021 (right to buy) · Derivative | 63,795 | $0.00 Strike: $235.13 | $0.00 |
DisclosureSEC source: 0000310764-21-000020 · wf-form4_161256189662920.xml · derivative · entry 1 Scannell Timothy J · CIK 0001451533 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,795 Underlying: Common Stock · 63,795 shares Expires 2031-02-02 F1 · derivative.exercise_date: Employee stock option granted pursuant to the Stryker Corporation 2011 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 15:08 UTC | STRYKER CORP SYK · Entity 369 | Exercise / conversionEmployee Stock Option granted 02/13/2013 (right to buy) · Derivative | 62,490 | $64.01 Strike: $64.01 | $3,999,984.90 |
DisclosureSEC source: 0000310764-20-000156 · wf-form4_160623047594185.xml · derivative · entry 8 Scannell Timothy J · CIK 0001451533 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,490 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Employee stock option granted pursuant to the Stryker Corporation 2006 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 15:08 UTC | STRYKER CORP SYK · Entity 369 | Exercise / conversionEmployee Stock Option granted 02/21/2012 (right to buy) · Derivative | 36,100 | $53.60 Strike: $53.60 | $1,934,960.00 |
DisclosureSEC source: 0000310764-20-000156 · wf-form4_160623047594185.xml · derivative · entry 7 Scannell Timothy J · CIK 0001451533 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,100 shares Expires 2022-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Employee stock option granted pursuant to the Stryker Corporation 2006 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.